ParkJ, SkålheggBS. Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer—a brief update. Front Immunol2025;16:1680838; doi: 10.3389/fimmu.2025.1680838.
2.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Management of immunotherapy-related toxicities (version 1.2026). 2026. https://www.nccn.org.
3.
BrahmerJR, LacchettiC, SchneiderBJ, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol2018;36(17):1714-1768; doi: 10.1200/JCO.2017.77.6385.
4.
YuH, ChenQ, HuW, et al.Incidence of thyroid adverse events following immune checkpoint inhibitor treatment in patients with baseline positive thyroid antibodies: A systematic review and meta-analysis. Front Oncol2025;15:1583592; doi: 10.3389/fonc.2025.1583592.
5.
SuzukiK, KobayashiT, IzuchiT, et al.Increased risk of hyperthyroidism induced by immune checkpoint inhibitors in patients with existing or prior Graves’ disease: A nested prospective cohort study with propensity score matching. Front Endocrinol (Lausanne)2025;16:1701500; doi: 10.3389/fendo.2025.1701500.
6.
TagamiT, KataiM, KinuyaS, et al.Guidelines for the diagnosis of Graves’ disease, hypothyroidism, painless thyroiditis, chronic thyroiditis (Hashimoto’s thyroiditis), and subacute thyroiditis (acute phase). Thyroid Science2025;2(4):100032; doi: 10.1016/j.thscie.2025.100032.
7.
de FiletteJ, AndreescuCE, CoolsF, et al.A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res2019;51(3):145-156; doi: 10.1055/a-0843-3366.
8.
YuanS, ZhaoX, LiuF, et al.The progression of TRAb-positive subacute thyroiditis and its differential diagnosis from Graves’ disease. Front Immunol2025;16:1727240; doi: 10.3389/fimmu.2025.1727240.
